The changes come after a rough quarter for Target, with sales at stores open for at least a year tumbling 3.8% compared to the same quarter a year prior. This was partly because of tariff-related ...

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

Target's decision to cease price matching with competitors like Amazon and Walmart marks a significant shift. Currently, ...

Under Target's current policy, the company will match the price of store-bought products if customers "then find the ...

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Yet another ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Find the latest Regeneron Pharmaceuticals, Inc. REGN analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.